- Report
- February 2025
- 218 Pages
Global
From €4368EUR$4,799USD£3,710GBP
- Report
- April 2025
- 200 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- April 2025
- 200 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- May 2024
- 140 Pages
Global
From €5915EUR$6,499USD£5,024GBP
- Report
- February 2025
- 184 Pages
Global
From €4096EUR$4,500USD£3,479GBP
- Report
- July 2024
- 70 Pages
Global
From €4323EUR$4,750USD£3,672GBP
- Report
- January 2023
- 127 Pages
Global
From €2048EUR$2,250USD£1,739GBP
- Report
- January 2024
- 200 Pages
Global
From €3777EUR$4,150USD£3,208GBP
- Report
- February 2024
- 181 Pages
Europe
From €4323EUR$4,750USD£3,672GBP
- Report
- February 2024
- 110 Pages
Global
From €4323EUR$4,750USD£3,672GBP
- Report
- February 2024
- 90 Pages
Global
From €4323EUR$4,750USD£3,672GBP
- Report
- August 2023
- 150 Pages
North America
From €4323EUR$4,750USD£3,672GBP
- Report
- March 2025
- 83 Pages
Global
From €3500EUR$4,119USD£3,077GBP

Ozempic (semaglutide) is a prescription medication used to treat type 2 diabetes. It belongs to a class of drugs known as glucagon-like peptide-1 (GLP-1) receptor agonists, which work by stimulating the release of insulin and reducing the amount of glucose produced by the liver. Ozempic is typically used in combination with diet and exercise to improve glycemic control in adults with type 2 diabetes. It can also be used as an adjunct to other diabetes medications, such as metformin or sulfonylureas.
Ozempic is part of a growing market of Endocrine and Metabolic Disorders Drugs, which includes medications used to treat a variety of conditions, such as obesity, thyroid disorders, and polycystic ovary syndrome. These drugs are used to help regulate hormones and metabolism, and can be used to improve overall health and quality of life.
Companies in the Ozempic market include Novo Nordisk, Eli Lilly, Sanofi, Merck, and AstraZeneca. Show Less Read more